Among older individuals with COPD, new use of long-acting β-agonists and anticholinergics is associated with similar increased risks of cardiovascular events. Close monitoring of COPD patients requiring long-acting bronchodilators is needed regardless of drug class.
No takes yet. Share an insight, caveat, or question.
Gershon et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: